A phase one clinical trial exploring a novel cell-based immunotherapy for breast cancer has been published in JAMA Oncology.

As dendritic cells increasingly become the ... heavily pretreated patients with advanced cancer are not ideal for testing vaccine-based immunotherapy given that these individuals are often highly ...

The immunotherapy leverages dendritic cells, critical components of the immune system that normally identify infection and ...

For the longest time, researchers had been looking at dendritic cells ... of anti-tumor immunity. I hope this will help us overcome resistance in more patients, making cancer immunotherapy a ...

No writing assistance was utilized in the production of this manuscript. Plasmacytoid dendritic cells (pDCs) are specialized APCs. Compared with other APCs, pDCs express a high level of TLR9 and ...

Bria-OTS+™ is an Off-The-Shelf (i.e. pre-manufactured and ready for use) cell-based ... long-lasting anti-tumor activity of our novel next-generation immunotherapy in multiple cancer models ...

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

With precision, scalability, and controlled immune activation, mRNA-based immunotherapy can encode proteins that stimulate the immune system to target and destroy cancer cells. Yet, naked mRNA is ...

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.